肥胖与川崎病及COVID-19相关儿童多系统炎症综合征的结局
这项国际队列研究基于国际川崎病登记处(IKDR)数据,纳入2020年1月1日至2022年7月31日期间42个中心、8个国家的1767例患儿,其中川崎病338例、MIS-C 1429例。MIS-C组超重(17.1% vs 11.5%)和肥胖(23.7% vs 11.5%)比例均显著高于川崎病组(P < .001),校正年龄、性别和种族后肥胖z评分仍显著更高。川崎病组中除ICU入住率外,肥胖类别与实验室指标或结局无关;MIS-C组中肥胖程度越高,休克、ICU入住、需正性肌力药的可能性越大,炎症标志物、肌酐和丙氨酸氨基转移酶水平也越高。肥胖类别与两组冠状动脉异常均无关。
要点
- MIS-C患儿肥胖比例为23.7%、超重17.1%,均显著高于川崎病患儿的11.5%和11.5%(P < .001)。
- MIS-C患儿中肥胖程度越高,休克、ICU入住和需正性肌力药的可能性越大,炎症标志物、肌酐和丙氨酸氨基转移酶水平也越高。
- 川崎病患儿中除ICU入住率外,肥胖类别与实验室指标或结局无关。
- 肥胖类别与MIS-C或川崎病的冠状动脉异常均无关。
- 作者认为,MIS-C患儿就诊时应将肥胖作为共病因素加以考虑。
适用人群与场景
- 2020年1月1日至2022年7月31日期间纳入国际川崎病登记处(IKDR)的MIS-C患儿(符合美国疾病控制与预防中心标准)和川崎病患儿(符合美国心脏协会标准)。
- 排除有近期COVID-19感染证据或COVID-19状态缺失/未知的川崎病患儿。
诊断标准与关键阈值
- MIS-C诊断采用美国疾病控制与预防中心(CDC)标准;川崎病诊断采用美国心脏协会(AHA)标准。
- 按体重指数(BMI)/体重z评分百分位等值将体重分为正常体重(BMI <85百分位)、超重(BMI ≥85至<95百分位)和肥胖(BMI ≥95百分位)。
研究设计与关键结果
- 研究类型为队列研究,分析国际川崎病登记处(IKDR)数据,共纳入1767例患儿,来自42个中心、8个国家;川崎病338例(中位年龄2.5岁,IQR 1.2-5.0;男性60.4%),MIS-C 1429例(中位年龄8.7岁,IQR 5.3-12.4;男性61.4%)。
- MIS-C组 vs 川崎病组的超重比例为17.1% vs 11.5%,肥胖比例为23.7% vs 11.5%,差异显著(P < .001);校正年龄、性别和种族后,MIS-C组肥胖z评分仍显著更高。
- 川崎病组中,除ICU入住率外,肥胖类别与实验室指标或结局无关。
- MIS-C组中,肥胖程度越高与更差的实验室指标和结局相关,包括休克、ICU入住和需正性肌力药的可能性更大,炎症标志物、肌酐和丙氨酸氨基转移酶水平更高。
- 肥胖类别与MIS-C或川崎病的冠状动脉异常均无关。
证据类型、等级与局限
- 证据类型:队列研究(国际多中心登记处数据分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,MIS-C患儿就诊时应将肥胖作为共病因素加以考虑。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Obesity may affect the clinical course of Kawasaki disease (KD) in children and multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19.
OBJECTIVE: To compare the prevalence of obesity and associations with clinical outcomes in patients with KD or MIS-C.
DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, analysis of International Kawasaki Disease Registry (IKDR) data on contemporaneous patients was conducted between January 1, 2020, and July 31, 2022 (42 sites, 8 countries). Patients with MIS-C (defined by Centers for Disease Control and Prevention criteria) and patients with KD (defined by American Heart Association criteria) were included. Patients with KD who had evidence of a recent COVID-19 infection or missing or unknown COVID-19 status were excluded.
MAIN OUTCOMES AND MEASURES: Patient demographic characteristics, clinical features, disease course, and outcome variables were collected from the IKDR data set. Using body mass index (BMI)/weight z score percentile equivalents, patient weight was categorized as normal weight (BMI <85th percentile), overweight (BMI ≥85th to <95th percentile), and obese (BMI ≥95th percentile). The association between adiposity category and clinical features and outcomes was determined separately for KD and MIS-C patient groups.
RESULTS: Of 1767 children, 338 with KD (median age, 2.5 [IQR, 1.2-5.0] years; 60.4% male) and 1429 with MIS-C (median age, 8.7 [IQR, 5.3-12.4] years; 61.4% male) were contemporaneously included in the study. For patients with MIS-C vs KD, the prevalence of overweight (17.1% vs 11.5%) and obesity (23.7% vs 11.5%) was significantly higher (P < .001), with significantly higher adiposity z scores, even after adjustment for age, sex, and race and ethnicity. For patients with KD, apart from intensive care unit admission rate, adiposity category was not associated with laboratory test features or outcomes. For patients with MIS-C, higher adiposity category was associated with worse laboratory test values and outcomes, including a greater likelihood of shock, intensive care unit admission and inotrope requirement, and increased inflammatory markers, creatinine levels, and alanine aminotransferase levels. Adiposity category was not associated with coronary artery abnormalities for either MIS-C or KD.
CONCLUSIONS AND RELEVANCE: In this international cohort study, obesity was more prevalent for patients with MIS-C vs KD, and associated with more severe presentation, laboratory test features, and outcomes. These findings suggest that obesity as a comorbid factor should be considered at the clinical presentation in children with MIS-C.
参考来源
- Khoury M, Harahsheh AS, Raghuveer G, et al. Obesity and Outcomes of Kawasaki Disease and COVID-19-Related Multisystem Inflammatory Syndrome in Children. JAMA Netw Open. 2023. PMID: 38064213. doi:10.1001/jamanetworkopen.2023.46829
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。